Subs	stitute for form 1449A/PTO			Complete if Known				
Constitute for form 1 110 11 10				Application Number	09/724,288	_		
				Filing Date	November 28, 2000	_		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Schenk, Dale B.	_		
				Art Unit	1649			
	(Use as many sheets as no	cessar	y)	Examiner Name	Daniel Kolker			
Sheet	1	of	3	Attorney Docket Number	15270J-004765US			

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No.1	Document Number Number Kind Code ^{2 (Fincen)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	892	6,923,964	08-02-2005	Schenk	
			U.S. PATENT API	PLICATIONS	
	899	11/358,951	02-22-2006	Solomon et al.	

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰			
		×							
						Γ			

Examiner Signature	Date Considered	,

EXAMINER initial if reference considered, whicher or not elastics is in conformance, with IMEP 800. Drew line through classics of first in conformance, and not considered. Include copy of the form with read commencation to applicable. Applicable is unique cased no elastigation number of positions). *Notice and the property of the form with read commencation to applicable. Applicable is unique cased no elastigation number of positions). *Notice and the property of the first interval to unique cased not expenditure and the property of the first interval proposed the sealing number of the paster document.
*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark her if English language Translation is attached.

Substitute	for form 1449B/PTO			Complete if Known			
				Application Number	09/724,288		
INFO	RMATION DIS	SCLOS	SURE	Filing Date	November 28, 2000	_	
STAT	TEMENT BY A	PPLIC	CANT	First Named Inventor	Schenk, Dale B.	_	
				Art Unit	1649	_	
	(Use as many sheets as	necessary)		Examiner Name	Daniel Kolker		
Sheet	2	of	3	Attorney Docket Number	15270J-004765US	_	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	898	ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertuss/s toxin subunit S1," PNAS, 87:1347-1351 (1990).					
	891	CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," <u>Drugs R D</u> , 7(3):187-193 (2006).					
	901	CASEY, S.O., "Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions," Amer J Neuroradiol, 21:1199-1206 (2000).					
	893	DE LA CRUZ et al, "Immumogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <u>J Biol Chem</u> , 263(9):4318-4322 (1988).					
	902	GILMAN, S. et al., "Clinical Effects of Aβ Immunization (AN1792) in Patients with AD in an Interrupted Trial," Neurology, 64:1553-1562 (2005).					
	896	GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Integr Comp Physiol</u> , 259:R1131-R1138 (1990).					
	895	KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <u>FEBS Letters</u> , 351:80-84 (1994).					
	889	LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <u>Proc. Natl. Acad. Sci.</u> , 95:13266-13271 (1998).					
	903	PCT Search Report of 10/01/2007 and Written Opinion of 10/01/2007 for application PCT/US07/09499.					

Examiner Signature Date Considered	
------------------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (opinion)**Applicant is unique and the citation designation is attached.

Substitute	for form 1449B/PTO			Complete if Known			
				Application Number	09/724,288		
INFO	RMATION DIS	SCLOS	SURE	Filing Date	November 28, 2000		
STATEMENT BY APPLICANT				First Named Inventor	Schenk, Dale B.		
				Art Unit	1649		
	(Use as many sheets as	necessary)		Examiner Name	Daniel Kolker		
Sheet	3	of	3	Attorney Docket Number	15270J-004765US		

	NON PATENT LITERATURE DOCUMENTS									
Examiner Initials *	r Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (it magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, c and/or country where published.									
	890	PEREZ et al., "The β-Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <u>J. Neurosci.</u> , 17(24):9407-9414 (1997).								
	897	WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," <u>Am J Pysiol Gastrointest Liver Physiol</u> , 259:G687-G691 (1990).								
	894	WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella," PNAS, 86:4726-4730 (1989).								
	900	Wyeth, Annual Review 2005: Creating ValueAdvancing Health (February 27, 2006).								

Examiner Signature	Date Considered	
O ignator o		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 603. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant unique citation designation number (opinion). **Applicant** unique citation designation is attached.

Applicant unique citation designation number (opinion). **Applicant** unique citation designation number (opinion).

Applicant unique citation designation number (opinion).

Applicant unique citation designation number (opinion).

Applicant unique citation designation number (opinion).

Applicant unique citation designation.

Applicant unique citation.

**Applicant*